Quick Answer
Guardant Health, Inc. reported Research And Development Expense of $364.19 million for the year ending 2025.
- Guardant Health, Inc. showed an increase of +4.7% in Research And Development Expense from 2024 to 2025.
- This data is from Guardant Health, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $7.25 million | Q1 2018: $8.26 million | Q2 2018: $11.55 million | Q3 2018: $14.25 million | Q1 2019: $16.32 million | Q2 2019: $19.53 million | Q3 2019: $24.57 million | Q1 2020: $37.02 million | Q2 2020: $36.32 million | Q3 2020: $36.25 million | Q1 2021: $55.51 million | Q2 2021: $63.72 million | Q3 2021: $70.97 million | Q1 2022: $81.76 million | Q2 2022: $85.46 million | Q3 2022: $100.02 million | Q1 2023: $93.13 million | Q2 2023: $90.36 million | Q3 2023: $93.85 million | Q1 2024: $83.80 million | Q2 2024: $83.10 million | Q3 2024: $87.31 million | Q1 2025: $88.52 million | Q2 2025: $87.45 million | Q3 2025: $89.96 million.
- Over the full 10 years of available data (2016 to 2025), Guardant Health, Inc.'s Research And Development Expense has grown by 3,253.8%.
- Historical annual values: Fiscal year 2025: $364.19 million | Fiscal year 2024: $347.75 million | Fiscal year 2023: $367.19 million | Fiscal year 2022: $373.81 million | Fiscal year 2021: $263.22 million | Fiscal year 2020: $149.86 million | Fiscal year 2019: $86.29 million | Fiscal year 2018: $50.71 million | Fiscal year 2017: $25.56 million | Fiscal year 2016: $10.86 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: